[Salicylamide-- a potential pain-remedy alternative in the analgesic asthma syndrome].
Central pathogenetic mechanism of the analgesics-asthma-syndrome is very probably an analgesics-conditioned inhibition of the prostaglandin-biosynthesis (cyclooxygenase). Salicylamide, an analgesic without effect on the prostaglandin synthesis was in the oral exposition test of 18 patients with proved analgesics-asthma-syndrome in the dosage of 500 mg subjectively and objectively tolerated without reaction. Body-plethysmographically in consistent thoracic gas volume a slight decrease of the airways resistance could be registered. At the model of the isolated trachea of guinea-pigs salicylamide, in contrast to indomethacin and phenazone (prostaglandin-synthesis inhibitory substances) did not lead to an increase of the acetylcholine-induced spasm. Salcylamide can, after a tolerability test, be recommended as alternative analgesic in the analgesics-asthma-syndrome in a dosage of 500 mg.
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000983:Antipyrine / Q000494:pharmacology; D001249:Asthma / Q000139:chemically induced*; D001986:Bronchial Spasm / Q000139:chemically induced; D016861:Cyclooxygenase Inhibitors; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D011448:Prostaglandin Antagonists; D012457:Salicylamides / Q000494:pharmacology* / Q000627:therapeutic use; D014132:Trachea / Q000187:drug effects
D000700:Analgesics; D016861:Cyclooxygenase Inhibitors; D011448:Prostaglandin Antagonists; D012457:Salicylamides; D000983:Antipyrine; D007213:Indomethacin
Salizylamid -- eine mögliche Schmerzmittelalternative beim Analgetika-Asthma-Syndrom.